A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 01 Feb 2018 Planned End Date changed from 8 Aug 2024 to 6 Sep 2022.
- 01 Feb 2018 Status changed from suspended to active, no longer recruiting.
- 27 Sep 2017 Planned number of patients changed from 120 to 121.